Haris Kamal, MD
Vascular Neurology · Houston, TXNPI 1619213386
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Microvention, Inc. at 34.6% of the total. Reporting peaked in 2024 at $10,368 and has fallen 94.7% since, to $554 in 2025.
Across 91 payments — averaging $226.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Microvention, Inc.$7K
- Philips North America LLC$6K
- Scientia Vascular$4K
- Medtronic$874
- Stryker$683
- Johnson & Johnson$574
- plus $1K from 13 others
Across 73 payments — averaging $3663.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Microvention, Inc.$267K
What the payments were for
- Consulting fees$8,20040%
- Speaking & faculty fees$5,25025%
- Travel & lodging$2,83214%
- Food & beverage$4,33921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Microvention, Inc. | 11 | $7,136 |
| Philips North America LLC | 9 | $5,800 |
| Scientia Vascular | 5 | $4,360 |
| Medtronic(2 entities) | 12 | $874 |
| Stryker | 14 | $683 |
| Johnson & Johnson(2 entities) | 8 | $574 |
| AstraZeneca | 3 | $256 |
| AbbVie(2 entities) | 9 | $213 |
| Phenox Inc. | 1 | $175 |
| Imperative Care, Inc | 1 | $149 |
| UCB, Inc. | 4 | $114 |
| Amgen | 3 | $54 |
| Azurity Pharmaceuticals, Inc. | 2 | $48 |
| Biogen | 3 | $45 |
| Cala Health, Inc. | 1 | $41 |
| Penumbra, Inc. | 2 | $40 |
| Genentech USA, Inc. | 1 | $22 |
| Microtransponder, Inc. | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IGT Enabling functio$5,800
- ERIC RETRIEVAL DEVICE$5,250
- WEB Aneurysm Embolization System$753
- SOFIA 6F-131CM STR$332
- STENT$332
- Pipeline$328
- Socrates 38$260
- BRILINTA$241
- Avenir Coil$175
- VANTAGE ANTERIOR FIXATION SYSTEM$169
- EVOLVE$152
- ZOOM REPERFUSION CATHETER$149
- ZOOM 88-T LARGE DISTAL PLATFORM$149
- Embotrap$147
- ATLAS$116
- BOTOX$108
How this compares
$20,621 in reported general payments places this provider in the 85th percentile of 76 vascular neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrilintaTicagrelor | 33 | $14,319 |
| ClopidogrelClopidogrel Bisulfate | 28 | $244 |
| Atorvastatin Calcium | 17 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta | $256 | $14,31933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 76 vascular neurology providers in Texas.
Other vascular neurology in Houston
- John VolpiHouston$407K
- Amrou SarrajHouston$182K
- Sunil ShethHouston$54K
- Sean SavitzHouston$20K
- Louise McCulloughHouston$14K
- Michael NahhasHouston$10K
- Rajan GadhiaHouston$5K
- Mohammad El-GhanemHouston$5K
- Robert RegenhardtHouston$5K
- Joseph FriesHouston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.